Everything below concerns Nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
ATC code G Genito-urinary system and sex hormones is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QG. ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.
== Preperitoneal space == Anteriorly, it forms the thin and fibrous preperitoneal fascia that is interposed between the transversalis fascia, and the parietal peritoneum. The preperitoneal fascia contains a variable amount of fat, loose connective tissue, and membranous tissue. It is provided with its own blood supply. The membranous component lies just deep to the transversalis fascia and has been construed as a second layer of the transversalis fascia by some authors.
Protein A/G is a recombinant fusion protein that combines IgG binding domains of both protein A and protein G. Protein A/G contains four Fc binding domains from protein A and two from protein G, yielding a final mass of 50,460 daltons. The binding of protein A/G is less pH-dependent than protein A, but otherwise has the additive properties of protein A and G. Protein A/G binds to all subclasses of human IgG, making it useful for purifying polyclonal or monoclonal IgG antibodies whose subclasses have not been determined. In addition, it binds to IgA, IgE, IgM and (to a lesser extent) IgD. Protein A/G also binds to all subclasses of mouse IgG but does not bind mouse IgA, IgM or serum albumin. This allows Protein A/G to be used for purification and detection of mouse monoclonal IgG antibodies, without interference from IgA, IgM and serum albumin. Mouse monoclonal antibodies commonly have a stronger affinity to the chimeric protein A/G than to either protein A or protein G. Protein A/G also has been used for purification of macaque IgG.
Synaptic plasticity, a particular type of neuroplasticity, is the ability of the nervous system to modify the intensity of interneuronal relationships (synapses), to establish new ones and to eliminate some. This property allows the nervous system to modify its structure and functionality in a more or less lasting way, depending on the events that influence it, such as experience or neuromodulation.
Sources: en.wikipedia.org
There are conflicting recommendations regarding whether to change the dosing of oral acetylcysteine after the administration of activated charcoal, and even whether the dosing of acetylcysteine needs to be altered at all. Intravenous acetylcysteine has no interaction with activated charcoal. Inducing vomiting with syrup of ipecac has no role in paracetamol overdose because the vomiting it induces delays the effective administration of activated charcoal and oral acetylcysteine. Liver injury is extremely rare after acute accidental ingestion in children under 6 years of age. Children with accidental exposures do not require gastrointestinal decontamination with either gastric lavage, activated charcoal, or syrup of ipecac.
The α1-adrenergic receptor antagonist prazosin is used off-label to treat insomnia, nightmares, and poor sleep quality in people with post-traumatic stress disorder (PTSD). It is clinically effective for this purpose. However, the drug is also an antihypertensive agent and can lower blood pressure, thereby producing side effects like dizziness and orthostatic hypotension. Certain non-selective hypnotics such as trazodone and tricyclic antidepressants (TCAs) like amitriptyline and trimipramine are also α1-adrenergic receptor antagonists. The combination of prazosin and the centrally-penetrant beta blocker (β-adrenergic receptor antagonist) timolol has been found to be synergistic in producing sedative and hypnotic effects in animals. Conversely, timolol alone produced no such effects. Centrally active beta blockers like propranolol and metoprolol on their own are not effective or clinically used as hypnotics and have actually been associated with insomnia as a side effect. Certain beta blockers like labetalol and carvedilol also block the α1-adrenergic receptor to varying extents and have been associated with somnolence as a side effect similarly. However, these two beta blockers have also been associated with insomnia as with selective beta blockers.
Time-resolved mass spectrometry (TRMS) is a strategy in analytical chemistry that uses mass spectrometry platform to collect data with temporal resolution. Implementation of TRMS builds on the ability of mass spectrometers to process ions within sub-second duty cycles. It often requires the use of customized experimental setups. However, they can normally incorporate commercial mass spectrometers. As a concept in analytical chemistry, TRMS encompasses instrumental developments (e.g. interfaces, ion sources, mass analyzers), methodological developments, and applications.
== Interactions == Nicergoline is known to enhance the cardiac depressive effects of propranolol. At high dosages, it is advisable to seek one's physician's guidance if combining with potent vasodilators such as bromocriptine, Ginkgo biloba, picamilon, vinpocetine or xantinol nicotinate.
A 2017 systematic review and meta-analysis of suvorexant for the treatment of insomnia found that the medication significantly increased the rate of somnolence by 3.5-fold, daytime sleepiness/sedation by 3.1-fold, fatigue by 2.1-fold, abnormal dreams by 2.1-fold, and dry mouth by 2.0-fold. Conversely, suvorexant did not significantly differ from placebo in the rates of any other assessed adverse effects. This included back pain, diarrhea, dizziness, falls, headache, car accidents/traffic violations, nasopharyngitis, nausea, potential drug misuse, suicidal ideation, complex sleep behaviors, hypnagogic or hypnopompic hallucinations, and sleep paralysis. The overall risk of any adverse event was increased 1.07-fold while discontinuation due to adverse events was unchanged (RRTooltip relative risk=0.93, 95% CITooltip confidence interval 0.60 to 1.44). Tolerance, dependence, withdrawal, and rebound effects do not appear to occur with suvorexant in the treatment of insomnia at studied doses. In three-month clinical studies, no rebound insomnia as assessed by measures of sleep onset or maintenance was observed with discontinuation of suvorexant at doses of 15 to 40 mg. Similarly, no withdrawal effects were observed with discontinuation of suvorexant at these doses. However, in other reports, some tolerance as assessed by diminishing somnolence and rebound insomnia upon discontinuation has been noted. The orexin neuropeptides augment the signaling of the mesolimbic dopamine reward pathway and are thought to potentiate hedonic tone.
Sources: en.wikipedia.org
=== Interstitial cystitis === Interstitial cystitis (IC) a type of painful bladder syndrome is a chronic disease of the bladder that causes feelings of pressure and pain in the bladder among other symptoms which can range from mild to severe. Urinary frequency and urgency are the most common symptoms associated with the disease. The exact causes of IC/BPS are unknown, but there is evidence of an association between increased permeability of the urothelium and IC. Since the purpose of the urothelium is to act as a highly resistant barrier, the loss of this function has serious clinical implications. Many patients with IC have exhibited a loss of umbrella cells.
=== Ribbon machine === Corning continued developing automated bulb-production machines, installing the Ribbon Machine in 1926 in its Wellsboro, Pennsylvania, factory. The Ribbon Machine surpassed any previous attempts to automate bulb production and was used to produce incandescent bulbs into the 21st century. The inventor, William Woods, along with his colleague at Corning Glass Works, David E. Gray, had created a machine that by 1939 was producing 1,000 bulbs per minute. The Ribbon Machine works by passing a continuous ribbon of glass along a conveyor belt, heated in a furnace, and then blown by precisely aligned air nozzles through holes in the conveyor belt into molds. Thus the glass bulbs or envelopes are created. A typical machine can produce 50,000 to 120,000 bulbs per hour, depending on the size of the bulb. By the 1970s, 15 ribbon machines installed in factories around the world produced the entire supply of incandescent bulbs. The filament and its supports are assembled on a glass stem, which is then fused to the bulb. The air is pumped out of the bulb, and the evacuation tube in the stem press is sealed by a flame. The bulb is then inserted into the lamp base, and the whole assembly tested. The 2016 closing of Osram-Sylvania's Wellsboro, Pennsylvania plant meant that one of the last remaining ribbon machines in the United States was shut down.
A biomaterial is any matter, surface, or construct that interacts with biological systems. Biomaterials science encompasses elements of medicine, biology, chemistry, tissue engineering, and materials science. Biomaterials can be derived either from nature or synthesized in a laboratory using a variety of chemical approaches using metallic components, polymers, bioceramics, or composite materials. They are often intended or adapted for medical applications, such as biomedical devices which perform, augment, or replace a natural function. Such functions may be benign, like being used for a heart valve, or may be bioactive with a more interactive functionality such as hydroxylapatite-coated hip implants. Biomaterials are also used every day in dental applications, surgery, and drug delivery. For example, a construct with impregnated pharmaceutical products can be placed into the body, which permits the prolonged release of a drug over an extended period of time. A biomaterial may also be an autograft, allograft or xenograft used as an organ transplant material.
== History == At least since 1875 there have been reports of automated devices for scientific investigation. These first devices were mostly built by scientists themselves in order to solve problems in the laboratory. After the second world war, companies started to provide automated equipment with greater and greater complexity. Automation steadily spread in laboratories through the 20th century, but then a revolution took place: in the early 1980s, the first fully automated laboratory was opened by Dr. Masahide Sasaki. In 1993, Dr. Rod Markin at the University of Nebraska Medical Center created one of the world's first clinical automated laboratory management systems. In the mid-1990s, he chaired a standards group called the Clinical Testing Automation Standards Steering Committee (CTASSC) of the American Association for Clinical Chemistry, which later evolved into an area committee of the Clinical and Laboratory Standards Institute. In 2004, the National Institutes of Health (NIH) and more than 300 nationally recognized leaders in academia, industry, government, and the public completed the NIH Roadmap to accelerate medical discovery to improve health. The NIH Roadmap clearly identifies technology development as a mission critical factor in the Molecular Libraries and Imaging Implementation Group (see the first theme – New Pathways to Discovery – at https://web.archive.org/web/20100611171315/http://nihroadmap.nih.gov/). Despite the success of Dr.
Overall, transacetalization plays a lesser role in forming protective acetals; they are formed as a rule from glycols through dehydration. Normally a simple glycol like ethylene glycol or 1,3-propadiol is used for acetalization. Modern variants also use glycols, but with the hydroxyl hydrogens replaced with a trimethylsilyl group. Acetals can be removed in acidic aqueous conditions. For those ends, the mineral acids are appropriate acids. Acetone is a common cosolvent, used to promote dissolution. For a non-acidic cleavage technique, a palladium(II) chloride acetonitrile complex in acetone or iron(III) chloride on silica gel can be performed with workup in chloroform. Cyclic acetals are very much more stable against acid hydrolysis than acyclic acetals. Consequently acyclic acetals are used practically only when a very mild cleavage is required or when two different protected carbonyl groups must be differentiated in their liberation. Besides the O,O-acetals, the S,O- and S,S-acetals also have an application, albeit scant, as carbonyl protecting groups too. Thiols, which one begins with to form these acetals, have a very unpleasant stench and are poisonous, which severely limit their applications. Thioacetals and the mixed S,O-acetals are, unlike the pure O,O-acetals, very much stabler against acid hydrolysis. This enables the selective cleavage of the latter in the presence of sulfur-protected carbonyl groups. The formation of S,S-acetals normally follows analogously to the O,O-acetals with acid catalysis from a dithiol and the carbonyl compound.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.